Literature DB >> 2901462

Butyrylcholinesterase in human brain and acetylcholinesterase in human plasma: trace enzymes measured by two-site immunoassay.

S Brimijoin1, P Hammond.   

Abstract

Enzyme-linked immunosorbent assays for acetylcholinesterase (AChE) and for butyrylcholinesterase (BuChE) were markedly more specific than conventional assays using selective enzyme inhibitors. The new assays were used with blood and brain samples containing traces of one enzyme dominated by large amounts of the other. The results showed that human plasma does contain AChE (8 ng/ml), even though its major cholinesterase is BuChE (3,300 ng/ml). BuChE immunoreactivity was not detected in human red blood cells but occurred in all brain regions. The cerebellum was the richest region tested (540 ng of BuChE/g of tissue), whereas the cerebral cortex was the poorest (240 ng of BuChE/g). However, because of the small local AChE content (99 ng/g), BuChE was the major cortical cholinesterase. The picture was reversed in the putamen, where BuChE immunoreactivity (340 ng/g) was far outweighed by that of AChE (6,100 ng/g).

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2901462     DOI: 10.1111/j.1471-4159.1988.tb03091.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  18 in total

Review 1.  Comparison of butyrylcholinesterase and acetylcholinesterase.

Authors:  A Chatonnet; O Lockridge
Journal:  Biochem J       Date:  1989-06-15       Impact factor: 3.857

2.  Methamidophos, dichlorvos, O-methoate and diazinon pesticides used in Turkey make a covalent bond with butyrylcholinesterase detected by mass spectrometry.

Authors:  Ozden Tacal; Oksana Lockridge
Journal:  J Appl Toxicol       Date:  2010-07       Impact factor: 3.446

3.  Use of a novel radiometric method to assess the inhibitory effect of donepezil on acetylcholinesterase activity in minimally diluted tissue samples.

Authors:  Tatsuya Kikuchi; Toshimitsu Okamura; Takuya Arai; Takayuki Obata; Kiyoshi Fukushi; Toshiaki Irie; Tetsuya Shiraishi
Journal:  Br J Pharmacol       Date:  2010-04       Impact factor: 8.739

4.  Magnetic electrochemical immunoassays with quantum dot labels for detection of phosphorylated acetylcholinesterase in plasma.

Authors:  Hua Wang; Jun Wang; Charles Timchalk; Yuehe Lin
Journal:  Anal Chem       Date:  2008-10-15       Impact factor: 6.986

5.  Recombinant human acetylcholinesterase is secreted from transiently transfected 293 cells as a soluble globular enzyme.

Authors:  B Velan; C Kronman; H Grosfeld; M Leitner; Y Gozes; Y Flashner; T Sery; S Cohen; R Ben-Aziz; S Seidman
Journal:  Cell Mol Neurobiol       Date:  1991-02       Impact factor: 5.046

6.  EQCM immunoassay for phosphorylated acetylcholinesterase as a biomarker for organophosphate exposures based on selective zirconia adsorption and enzyme-catalytic precipitation.

Authors:  Hua Wang; Jun Wang; Daiwon Choi; Zhiwen Tang; Hong Wu; Yuehe Lin
Journal:  Biosens Bioelectron       Date:  2008-12-14       Impact factor: 10.618

7.  A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease.

Authors:  Agneta Nordberg; Clive Ballard; Roger Bullock; Taher Darreh-Shori; Monique Somogyi
Journal:  Prim Care Companion CNS Disord       Date:  2013-03-07

8.  The peptidase activity of human serum butyrylcholinesterase: studies using monoclonal antibodies and characterization of the peptidase.

Authors:  R V Rao; A S Balasubramanian
Journal:  J Protein Chem       Date:  1993-02

9.  Polyproline-rich peptides associated with Torpedo californica acetylcholinesterase tetramers.

Authors:  Lilly Toker; Israel Silman; Tzviya Zeev-Ben-Mordehai; Joel L Sussman; Lawrence M Schopfer; Oksana Lockridge
Journal:  Chem Biol Interact       Date:  2020-02-20       Impact factor: 5.192

10.  Altered levels of acetylcholinesterase in Alzheimer plasma.

Authors:  María-Salud García-Ayllón; Iolanda Riba-Llena; Carol Serra-Basante; Jordi Alom; Rathnam Boopathy; Javier Sáez-Valero
Journal:  PLoS One       Date:  2010-01-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.